医学
肾脏疾病
肾病
不利影响
达帕格列嗪
疾病
内科学
糖尿病
重症监护医学
内分泌学
2型糖尿病
作者
Jonathan Barratt,Jürgen Floege
标识
DOI:10.1016/j.kint.2021.04.002
摘要
Despite supportive measures that slow the rate of progression of chronic kidney disease in IgA nephropathy, many patients still progress to end-stage kidney disease. Currently employed immunosuppressive strategies lack conclusive efficacy data, while there is evidence for treatment-emergent toxicity. A subanalysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease Trial, which encompassed 270 patients with a diagnosis of IgA nephropathy, now provides early evidence that dapagliflozin may be a safe and effective addition to current standard of care in IgA nephropathy.
科研通智能强力驱动
Strongly Powered by AbleSci AI